Home › Research › Biomarkers
Neurofilaments as biomarkers in neurological disorders - towards clinical application
Khalil M, Teunissen CE, Lehmann S, Otto M, Piehl F, Ziemssen T, Bittner S, Sormani MP et al.. Nature reviews. Neurology, 2024-04-12
Topic: Brain proteins, microglia and lab models
Plain-language summary
Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-axonal injury. The advent of highly sensitive analytical platforms that enable reliable quantification of neurofilaments in blood samples and simplify longitudinal follow-up has paved the way for the development of neurofilaments as a biomarker in clinical practice. Potential applications include assessment of disease activity, monitoring of treatment responses, and determining prognosis in many acute and chronic neurological disorders as well as their use as an outcome measure in trials of novel therapies. Progress has now moved the measurement of neurofilaments to the doorstep of routine clinical practice for the evaluation of individuals. In this Review, we first outline current knowledge on the structure and function of neurofilaments. We then discuss analytical and statistical approaches and challenges in determining neurofilament levels in different clinical contexts and assess the implications of neurofilament light chain (NfL) levels in normal ageing and the confounding factors that need to be considered when interpreting NfL measures. In addition, we summarize the current value and potential clinical applications of neurofilaments as a biomarker of neuro-axonal damage in a range of neurological disorders, including multiple sclerosis, Alzheimer disease, frontotemporal dementia, amyotrophic lateral sclerosis, stroke and cerebrovascular disease, traumatic brain injury, and Parkinson disease. We also consider the steps needed to complete the translation of neurofilaments from the laboratory to the management of neurological diseases in clinical practice.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This review says blood and fluid levels of neurofilament proteins are a validated sign of nerve-fibre damage, and that sensitive blood tests have brought measurement "to the doorstep of routine clinical practice" for tracking disease activity, treatment response and prognosis. It describes a monitoring tool, not a treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., et al. (2024). Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nature reviews. Neurology. https://doi.org/10.1038/s41582-024-00955-x
Vancouver
Khalil M, Teunissen CE, Lehmann S, Otto M, Piehl F, Ziemssen T, et al. Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nature reviews. Neurology. 2024. doi:10.1038/s41582-024-00955-x. PMID: 38609644.
BibTeX
@article{khalil2024-38609644,
author = {Khalil, M. and Teunissen, C. E. and Lehmann, S. and Otto, M. and Piehl, F. and Ziemssen, T. and Bittner, S. and Sormani, M. P. and others},
title = {{Neurofilaments as biomarkers in neurological disorders - towards clinical application}},
journal = {Nature reviews. Neurology},
year = {2024},
doi = {10.1038/s41582-024-00955-x},
pmid = {38609644},
url = {https://doi.org/10.1038/s41582-024-00955-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Progress has now moved the measurement of neurofilaments to the doorstep of routine clinical practice for the evaluation of individuals.
- In this Review, we first outline current knowledge on the structure and function of neurofilaments.
- We then discuss analytical and statistical approaches and challenges in determining neurofilament levels in different clinical contexts and assess the implications of neurofilament light chain (NfL) levels in normal ageing and the confounding factors that need to be considered when interpreting NfL measures.
- In addition, we summarize the current value and potential clinical applications of neurofilaments as a biomarker of neuro-axonal damage in a range of neurological disorders, including multiple sclerosis, Alzheimer disease, frontotemporal dementia, amyotrophic lateral sclerosis, stroke and cerebrovascular disease, traumatic brain injury, and Parkinson disease.
- We also consider the steps needed to complete the translation of neurofilaments from the laboratory to the management of neurological diseases in clinical practice.
Why it matters
This review says blood and fluid levels of neurofilament proteins are a validated sign of nerve-fibre damage, and that sensitive blood tests have brought measurement "to the doorstep of routine clinical practice" for tracking disease activity, treatment response and prognosis. The marker rises in many conditions — including multiple sclerosis, ALS, stroke, brain injury and frontotemporal dementia as well as Alzheimer's — so a high level signals damage, not a specific diagnosis, and the authors stress that normal ageing and other confounders must be considered when reading a result. It describes a monitoring tool, not a treatment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 67/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nature reviews. Neurology) |
| Journal's citation record | 3 / 4 | Nature Reviews Neurology: journal h-index 269 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 445 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 111.2 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 5 / 6 | Cited 29.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 10 other studies in this library |
| Still being cited | 4 / 4 | Cited 445 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jens Kühle: h-index 94 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 38 institution(s) in 12 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38609644) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41582-024-00955-x
- PubMed: 38609644
- Original source →
- Free full text: discovery.ucl.ac.uk →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.